276 related articles for article (PubMed ID: 12386264)
21. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2).
Fan SL; Schroeder NJ; Calverley MJ; Burrin JM; Makin HL; Cunningham J
Nephrol Dial Transplant; 2000 Dec; 15(12):1943-9. PubMed ID: 11096138
[TBL] [Abstract][Full Text] [Related]
22. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
23. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.
Cheng S; Coyne D
Expert Opin Pharmacother; 2006 Apr; 7(5):617-21. PubMed ID: 16553577
[TBL] [Abstract][Full Text] [Related]
24. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
25. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
26. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
27. Use of vitamin D analogs in chronic renal failure.
Kim G; Sprague SM
Adv Ren Replace Ther; 2002 Jul; 9(3):175-83. PubMed ID: 12203199
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
29. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
[TBL] [Abstract][Full Text] [Related]
30. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
Schömig M; Ritz E
Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
[TBL] [Abstract][Full Text] [Related]
31. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
32. [Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].
Morii H
Clin Calcium; 2005 Jan; 15(1):29-33. PubMed ID: 15632470
[TBL] [Abstract][Full Text] [Related]
33. Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells.
Segersten U; Björklund P; Hellman P; Akerström G; Westin G
Clin Endocrinol (Oxf); 2007 Mar; 66(3):399-404. PubMed ID: 17302875
[TBL] [Abstract][Full Text] [Related]
34. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
[TBL] [Abstract][Full Text] [Related]
35. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
36. What is the optimal regimen for vitamin D?
Cunningham J
Kidney Int Suppl; 1999 Dec; 73():S59-64. PubMed ID: 10633466
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
38. Use of vitamin D analogs in renal osteodystrophy.
Johnson WJ
Semin Nephrol; 1986 Mar; 6(1):31-41. PubMed ID: 3037668
[No Abstract] [Full Text] [Related]
39. Therapeutic uses of vitamin D analogues.
Brown AJ
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S3-S19. PubMed ID: 11689383
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
